Local Anesthetics

Correct Answer

C — Bupivacaine

Rationale

Bupivacaine is absolutely contraindicated for intravenous regional anesthesia (the Bier block technique, in which local anesthetic is injected into a limb isolated by tourniquet). If the tourniquet deflates prematurely, a bolus of bupivacaine enters the systemic circulation and can cause cardiac arrest that is extremely difficult to reverse — a consequence of bupivacaine's tight, slow-dissociating binding to cardiac sodium channels. Lidocaine is the agent of choice for intravenous regional anesthesia and is the only local anesthetic routinely used for this technique. Chloroprocaine and prilocaine have been used in some protocols but are not the standard agents; neither carries the catastrophic cardiac risk that makes bupivacaine absolutely prohibited in this setting.

Correct Answer

A — Prilocaine

Rationale

Prilocaine is the amide local anesthetic most associated with methemoglobinemia (a condition in which hemoglobin iron is oxidized from the ferrous to the ferric state, impairing oxygen transport). The responsible agent is ortho-toluidine, a hepatic metabolite of prilocaine that oxidizes hemoglobin iron. Prilocaine's methemoglobinemia risk is clinically relevant in its role as one of the two components of EMLA cream (a eutectic mixture of local anesthetics combining lidocaine and prilocaine) and limits its use in infants under three months of age. Bupivacaine and ropivacaine are amide local anesthetics not associated with methemoglobinemia. Chloroprocaine is an ester local anesthetic also not associated with this adverse effect.

Correct Answer

D — Schedule II

Rationale

Cocaine is classified as a Schedule II controlled substance — a category that includes drugs with accepted medical use but high potential for abuse and dependence. Despite its legitimate clinical application as a topical local anesthetic for nasal and pharyngeal procedures (where it provides simultaneous anesthesia and vasoconstriction), cocaine's high abuse potential and the availability of alternative agents have made it the only local anesthetic with this regulatory classification. Schedule III and Schedule Four designations apply to drugs with progressively lower abuse potential. No local anesthetic is unscheduled.

Correct Answer

B — Lidocaine and prilocaine

Rationale

EMLA cream combines lidocaine and prilocaine in a 1:1 ratio. A eutectic mixture (a combination that melts at a lower temperature than either component alone) produces a liquid at room temperature that penetrates intact skin when applied under an occlusive dressing for 45 to 60 minutes. The preparation provides effective topical anesthesia for venipuncture, lumbar puncture, and minor dermatological procedures. The prilocaine component carries a small risk of methemoglobinemia through its metabolite ortho-toluidine, which is clinically relevant in infants under three months of age whose methemoglobin-reducing capacity is immature. Neither bupivacaine, ropivacaine, nor tetracaine is a component of EMLA cream.

Correct Answer

C — Ropivacaine

Rationale

Ropivacaine is classified as a motor-sparing local anesthetic — it produces more selective sensory blockade relative to motor blockade at lower concentrations compared to bupivacaine. This property makes ropivacaine a preferred agent for labor epidural analgesia, where effective pain relief with preserved motor function allows patients to remain ambulatory. Ropivacaine is also less cardiotoxic than bupivacaine, which further favors its use in obstetric settings. Bupivacaine produces more pronounced motor blockade at equivalent analgesic concentrations and is more cardiotoxic. Tetracaine is a long-acting ester used primarily for spinal anesthesia and ophthalmic procedures, not for epidural labor analgesia. Mepivacaine is an intermediate-duration amide without the motor-sparing classification associated with ropivacaine.

Correct Answer

A — Cocaine

Rationale

Cocaine is the only local anesthetic that produces vasoconstriction at the site of administration. All other local anesthetics cause vasodilation at clinical concentrations by relaxing vascular smooth muscle, which accelerates systemic drug absorption and shortens duration of effect — the primary reason epinephrine (a drug that activates alpha-1 adrenergic receptors to constrict blood vessels) is added to many local anesthetic solutions. Cocaine's unique vasoconstrictive property makes it particularly useful for procedures involving nasal and pharyngeal mucosa, where simultaneous anesthesia and reduced bleeding are both desirable. Lidocaine, bupivacaine, and ropivacaine all cause vasodilation and do not share cocaine's vasoconstrictive classification.

Correct Answer

B — Lipid solubility

Rationale

Lipid solubility is the property that determines both the intrinsic potency and the duration of action of a local anesthetic. Drugs with higher lipid solubility penetrate nerve membranes more readily and bind to membrane proteins with greater affinity, producing blockade at lower concentrations — higher potency. Because highly lipid-soluble drugs also partition into the lipid-rich myelin sheath and nerve membrane and are released slowly from these compartments, their duration of action is prolonged. Bupivacaine is an example of a highly lipid-soluble agent with correspondingly high potency and long duration; procaine is poorly lipid-soluble and is among the least potent and shortest-acting agents. The acid dissociation constant (pKa) governs speed of onset rather than potency or duration. Degree of ionization at physiological pH is a consequence of pKa rather than an independent property. Molecular weight is not a primary pharmacokinetic determinant of local anesthetic clinical behavior.

Correct Answer

D — Protein binding

Rationale

Protein binding is the primary determinant of local anesthetic duration of action independent of lipid solubility. Local anesthetics bind to plasma proteins — primarily alpha-1 acid glycoprotein — and to proteins within the nerve membrane. A drug with high protein binding dissociates slowly from these binding sites and therefore remains at the site of action longer, prolonging the period of effective blockade. Bupivacaine is approximately 95% protein-bound and has a correspondingly long duration of action. Chloroprocaine has low protein binding and is hydrolyzed rapidly by plasma pseudocholinesterase, producing the shortest duration of any injectable local anesthetic. The acid dissociation constant (pKa) governs speed of onset. Degree of ionization at physiological pH is a consequence of pKa, not an independent property. Molecular weight is not a primary determinant of duration.

Correct Answer

A — Acid dissociation constant (pKa) — agents with pKa closer to physiological pH have faster onset

Rationale

The acid dissociation constant (pKa) is the primary determinant of local anesthetic speed of onset. Local anesthetics are weak bases that must cross the nerve membrane in their un-ionized (uncharged) form before the ionized form can bind the sodium channel from inside the axon. At physiological tissue pH of 7.4, a drug with a pKa closer to 7.4 has a larger fraction of molecules in the un-ionized form and therefore more drug immediately available to penetrate the nerve membrane — producing faster onset. Lidocaine has a pKa of 7.9 and has faster onset than bupivacaine, whose pKa of 8.1 means a smaller un-ionized fraction at the same pH. Lipid solubility governs potency and duration, not onset speed. Protein binding governs duration. Molecular weight is not a primary determinant of onset speed in this drug class.

Correct Answer

C — Para-aminobenzoic acid — the hydrolysis product shared by all ester local anesthetics — is the allergen; cross-reactivity within the ester class is possible

Rationale

Allergic reactions to ester local anesthetics are mediated not by the ester drug itself but by para-aminobenzoic acid — the metabolite released when ester local anesthetics are hydrolyzed by plasma pseudocholinesterase (an enzyme in the blood that breaks down ester bonds). Para-aminobenzoic acid is a well-recognized allergen capable of triggering immunoglobulin E-mediated hypersensitivity. Because all ester local anesthetics produce para-aminobenzoic acid on hydrolysis, a patient sensitized to this metabolite may react to any ester agent — making cross-reactivity within the ester class possible. A patient with a documented ester allergy should receive an amide local anesthetic (using a preservative-free formulation) rather than a different ester. Option A has the allergen identification reversed. Option B invokes an ester-bond-directed immune response that does not reflect the actual mechanism. Option D attributes the allergy to the enzyme rather than the metabolite, which is pharmacologically unsupported.

Correct Answer

B — Multi-dose vials of amide local anesthetics contain methylparaben — a preservative structurally similar to para-aminobenzoic acid — which triggered the reaction in this para-aminobenzoic acid-sensitive patient

Rationale

True immunoglobulin E-mediated allergy to amide local anesthetics is extremely rare. When a patient with a known ester allergy appears to react to an amide agent from a multi-dose vial, the responsible agent is typically methylparaben — an antimicrobial preservative added to multi-dose vials that is structurally similar to para-aminobenzoic acid. A patient sensitized to para-aminobenzoic acid (the ester allergy metabolite) may react to methylparaben due to this structural similarity. The solution is to use a preservative-free single-dose amide formulation, which eliminates the methylparaben exposure. Option A is a critical misconception — amide and ester local anesthetics do not cross-react; this is one of the most important clinical points in local anesthetic allergy management. Option C is pharmacologically unsupported — lidocaine is not metabolized to para-aminobenzoic acid; it is an amide drug metabolized by hepatic enzymes to entirely different metabolites. Option D mischaracterizes the frequency of true amide allergy, which is genuinely rare.

Correct Answer

D — Amide local anesthetics are metabolized by hepatic enzymes, and severe liver disease impairs this metabolism, leading to drug accumulation and increased toxicity risk

Rationale

Amide local anesthetics — including lidocaine, bupivacaine, ropivacaine, mepivacaine, and prilocaine — require hepatic enzyme metabolism for elimination. In a patient with severe liver disease such as cirrhosis, the capacity of the liver to metabolize these drugs is reduced, leading to slower clearance, higher plasma concentrations after a given dose, and increased risk of systemic toxicity. Dose reduction and careful monitoring are warranted, and an ester local anesthetic may be a preferable alternative since esters are hydrolyzed in the bloodstream by plasma pseudocholinesterase — a pathway that does not depend on hepatic function. Option A misidentifies the route of elimination; amide local anesthetics are metabolized hepatically, not renally excreted. Option B confuses the two metabolic pathways — plasma pseudocholinesterase hydrolysis is the ester pathway, not the amide pathway. Option C reverses the class assignments entirely; esters are metabolized by plasma pseudocholinesterase, not by hepatic enzymes.

Correct Answer

A — Ester local anesthetics accumulate in the plasma due to impaired hydrolysis, producing prolonged duration and increased systemic toxicity risk

Rationale

Ester local anesthetics are metabolized in the bloodstream by pseudocholinesterase — also called plasma cholinesterase or butyrylcholinesterase — an enzyme that circulates in the plasma and hydrolyzes ester bonds. In patients with pseudocholinesterase deficiency (which may be genetic or acquired through liver disease, malnutrition, or certain medications), this hydrolysis is slowed. Ester local anesthetics accumulate in the plasma, producing prolonged duration of action and elevated systemic drug concentrations that increase toxicity risk. In such patients, an amide local anesthetic is the appropriate alternative, because amide drugs are metabolized by hepatic enzymes and are entirely unaffected by pseudocholinesterase activity. Option B mischaracterizes the metabolic backup — there is no significant hepatic pathway for ester local anesthetics. Option C reverses the class assignments; pseudocholinesterase metabolizes esters, not amides. Option D mischaracterizes the enzymatic role — reducing pseudocholinesterase activity would slow, not increase, para-aminobenzoic acid production from ester hydrolysis.

Correct Answer

C — Cocaine blocks the reuptake of norepinephrine into nerve terminals, increasing norepinephrine concentration at vascular smooth muscle receptors and producing vasoconstriction

Rationale

Cocaine produces vasoconstriction through a mechanism entirely distinct from its sodium channel blockade: it inhibits the norepinephrine reuptake transporter at sympathetic nerve terminals. Norepinephrine released into the synaptic cleft is normally removed by reuptake into the presynaptic terminal; cocaine blocks this transporter, allowing norepinephrine to accumulate at vascular smooth muscle receptors. The resulting alpha-1 adrenergic receptor stimulation produces vasoconstriction. This property makes cocaine uniquely useful for nasal and pharyngeal procedures where simultaneous anesthesia and vasoconstriction reduce bleeding. All other local anesthetics relax vascular smooth muscle, causing vasodilation. Option A describes direct receptor agonism — cocaine does not directly activate adrenergic receptors but rather prevents norepinephrine removal. Option B invokes calcium channel inhibition, which is not the mechanism of cocaine's vasoconstrictive effect. Option D attributes the effect to adrenal epinephrine release, which does not account for the local vasoconstrictive action at the site of topical application.

Correct Answer

D — Lidocaine from a preservative-free single-dose vial, because amide and ester local anesthetics do not cross-react

Rationale

Amide and ester local anesthetics do not cross-react. The allergen in ester allergy is para-aminobenzoic acid — the metabolite produced when ester local anesthetics are hydrolyzed by plasma pseudocholinesterase. Amide local anesthetics do not produce para-aminobenzoic acid; they are metabolized by hepatic enzymes to entirely different metabolites. A patient with confirmed ester allergy can safely receive an amide local anesthetic. The preservative-free single-dose vial formulation is specified to avoid methylparaben — a preservative in multi-dose amide vials that is structurally similar to para-aminobenzoic acid and could trigger a reaction in a para-aminobenzoic acid-sensitive patient. Tetracaine and chloroprocaine are both ester local anesthetics that share the para-aminobenzoic acid metabolite with procaine; substituting one ester for another does not eliminate the allergy risk. Cocaine is also an ester and carries the same cross-reactivity concern.

Correct Answer

B — Bupivacaine is approximately 95% protein-bound and dissociates slowly from protein binding sites in the nerve membrane, prolonging the duration of blockade

Rationale

Bupivacaine is approximately 95% protein-bound — among the highest protein binding of any local anesthetic. When a local anesthetic binds to proteins within the nerve membrane, the rate of dissociation from those binding sites determines how long the drug remains at its site of action. Bupivacaine's high protein binding means it dissociates slowly, prolonging the duration of nerve blockade well beyond what lidocaine produces. Lidocaine is approximately 65% protein-bound and has an intermediate duration of action. Option A correctly identifies that bupivacaine has a higher pKa than lidocaine, but a higher pKa predicts slower onset — not longer duration. pKa governs the fraction of un-ionized drug available at physiological pH and therefore onset speed, not the time the drug remains bound at the nerve. Option C is pharmacologically reversed — bupivacaine, like most local anesthetics, causes vasodilation rather than vasoconstriction; only cocaine produces vasoconstriction among local anesthetics. Option D is partially correct — bupivacaine's high lipid solubility also contributes to its long duration — but the question asks for the primary determinant cited in the context of protein binding being independent of lipid solubility.

Correct Answer

A — An amide local anesthetic, because amides are metabolized by hepatic enzymes and are unaffected by pseudocholinesterase deficiency

Rationale

Ester local anesthetics depend on plasma pseudocholinesterase for their metabolism in the bloodstream. In patients with pseudocholinesterase deficiency, ester hydrolysis is impaired, causing the drug to accumulate and producing prolonged duration and elevated plasma concentrations that increase toxicity risk. Amide local anesthetics — lidocaine, bupivacaine, ropivacaine, mepivacaine, and prilocaine — are metabolized by hepatic enzymes and have no dependence on pseudocholinesterase activity. They can be used at standard doses in patients with pseudocholinesterase deficiency without any modification related to this enzyme. Option B proposes using an ester agent, which is the class that would be impaired by this patient's deficiency. Option C similarly proposes an ester agent; the degree of residual enzyme activity is unpredictable and this approach does not eliminate the risk. Option D incorrectly states that pseudocholinesterase plays a role in amide metabolism — it does not; amide metabolism is entirely hepatic.

Correct Answer

C — Bupivacaine binds cardiac sodium channels rapidly but dissociates very slowly, so channels do not recover between heartbeats and conduction block deepens progressively with each successive beat

Rationale

Bupivacaine's cardiac toxicity is determined by its kinetics of sodium channel interaction in the heart. It binds cardiac sodium channels rapidly ("fast in") but dissociates from them very slowly ("slow out") — in stark contrast to lidocaine, which both binds and dissociates rapidly. Between each heartbeat, the brief period of diastole allows lidocaine to partially release from cardiac channels, so some channel recovery occurs. Bupivacaine's slow dissociation means it does not release its cardiac channels during diastole; with each successive action potential, more channels accumulate drug. The result is progressive deepening of cardiac conduction block that resists standard resuscitation. Intravenous lipid emulsion therapy is used specifically for this situation — it creates a lipid phase in the blood that partitions bupivacaine out of cardiac tissue, gradually reducing the drug concentration at its target. Recovery requires sustained resuscitation efforts. Option A addresses tissue distribution but does not explain the channel kinetics that make resuscitation difficult. Option B confuses the sequence — central nervous system toxicity precedes cardiovascular toxicity at lower concentrations, but the distinctive resuscitation difficulty is a cardiac channel kinetics problem, not a respiratory one. Option D mischaracterizes the mechanism — bupivacaine blockade is reversible; the difficulty in resuscitation lies in the slow dissociation kinetics, not in irreversible channel destruction.